Prime Medicine (PRME) risk factors
Item 1A of every Prime Medicine, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors73 risks11 new11 dropped22 reworded
Prime Medicine added 11 new risk disclosures covering financial instability, regulatory complexities for gene editing, data privacy, ESG, and social media. The company updated risks on collaboration dependencies, macroeconomic factors, and patent protection standards.
Filed Mar 03, 2026 - FY2024 10-K risk factors73 risks
Prime Medicine faces substantial going concern doubt with an accumulated deficit of $687.2 million as of December 31, 2024. The company relies entirely on third-party licenses like Broad Institute and Beam Therapeutics without owning issued patents. Operations depend heavily on unproven Prime Editing technology and early-stage rare disease pipelines.
Filed Feb 28, 2025